Full text is available at the source.
Use of glucagon-like peptide-1 receptor agonists in Japanese people with type 2 diabetes
Updated
Abstract
The proportion of patients receiving glucagon-like peptide-1 receptor agonists (GLP-1RAs) in Japan increased from 3.6% to 9.6% between 2016 and 2020.
- Among GLP-1RA-naïve patients (n = 569), HbA1c decreased by -0.6% (95% CI -0.7, -0.5) six months after treatment initiation.
- Mean body weight decreased by -1.05 kg (95% CI -1.31, -0.80) within the same timeframe.
- Mean body mass index (BMI) decreased by -0.43 kg/m2 (95% CI -0.53, -0.32) at six months.
- The proportion of GLP-1RA-naïve patients achieving HbA1c < 7.0% increased from 16% to 27%, and those achieving HbA1c < 8.0% increased from 43% to 65% after six months.
- An HbA1c reduction of ≥1.0% was observed in 33% of patients after six months.
Simplified